May. 17 at 10:07 PM
$IOVA $VCEL the amount of publicity and recognition that Iovance is getting right now is about to be the main driver for stock appreciation… for every patient telling their story, physician celebrating the results, scientist validating the data, the narrative changes on Wall Street. It’s unquantifiable but I’ve seen it before. It reminds me of VCEL at
$2.50, even after MACI was approved. I was lucky enough to have acquired plenty of shares. I couldn’t believe Wall Street didn’t initially recognize the first FDA approved autologous cell therapy. Then the traction started, not immediate but enough to know the market was accepting a new standard. Out of nowhere the market recognized how special the treatment was… Mostly after they started hearing testimonials from patients
